Metabolic Diseases | iPharmaCenter

Tirzepatide significantly reduced the risk of progression to type 2 diabetes in adults with prediabetes and obesity, preventing most from developing the disease over 176 weeks | iPharmaCenter

Treatment with tirzepatide in adults with prediabetes and either obesity or overweight conditions has led to substantial weight loss and...

Pfizer decides to continue development of GLP agonist Danuglipron | iPharmaCenter

Pfizer Progresses with Once-Daily Oral GLP-1 Receptor Agonist Danuglipron Pfizer has reported positive pharmacokinetic results from...

Obesity News | Overweight | Treatments |Updates | iPharmaCenter

Boehringer Ingelheim has revealed its strategic plan to propel survodutide, a dual agonist for the glucagon/GLP-1 receptor, into three...

Diabetes mellitus News | iPharmaCenter

Sanofi has reduced the price of Lantus (insulin glargine injection) 100 Units/mL by 78%, which is Sanofi's most widely prescribed...

NASH News | Updates | Liver disease

May 26, 2022 FDA granted fast track designation for ervogastat/clesacostat for the treatment of NASH Pizer announced that the U.S. Food...